Payment overview · 2025
General Payments
$21.12
1 reported records · 1 companies
Healthcare provider profile · identity verified
Kevin Wineinger, MD
Allopathic & Osteopathic Physicians|Internal Medicine · KOKOMO, IN · NPI 1083908503
Verified facts
What the public records show
CMS Open Payments records show Kevin Wineinger, MD received $21.12 in general payments during 2025 across 1 reported records.
GlaxoSmithKline, LLC. accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $21.12 | 100.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $21.12 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $21.12 | 1 | 2025 |
Source payment records
|
|||||
| PEDIARIX Normalized: pediarix |
Biological | GlaxoSmithKline, LLC. | $21.12 | 1 | 2025 |
Source payment records
|
|||||
| ROTARIX Normalized: rotarix |
Biological | GlaxoSmithKline, LLC. | $21.12 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
41 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1181 | 237 |
| Amlodipine Besylate | Amlodipine Besylate | 652 | 130 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 472 | 108 |
| Gabapentin | Gabapentin | 432 | 91 |
| Lisinopril | Lisinopril | 396 | 77 |
| Losartan Potassium | Losartan Potassium | 360 | 69 |
| Metoprolol Succinate | Metoprolol Succinate | 345 | 63 |
| Pantoprazole Sodium | Pantoprazole Sodium | 334 | 53 |
| Furosemide | Furosemide | 274 | 48 |
| Levothyroxine Sodium | Levothyroxine Sodium | 255 | 45 |
| Metformin Hcl | Metformin Hcl | 255 | 57 |
| Hydrochlorothiazide | Hydrochlorothiazide | 251 | 44 |
| Omeprazole | Omeprazole | 242 | 48 |
| Fluticasone Propionate | Fluticasone Propionate | 196 | 51 |
| Tamsulosin Hcl | Tamsulosin Hcl | 177 | 38 |
| Carvedilol | Carvedilol | 172 | 33 |
| Potassium Chloride | Potassium Chloride | 171 | 26 |
| Eliquis | Apixaban | 166 | 32 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 160 | 30 |
| Sertraline Hcl | Sertraline Hcl | 159 | 29 |
| Diclofenac Sodium | Diclofenac Sodium | 153 | 33 |
| Trulicity | Dulaglutide | 142 | 30 |
| Trazodone Hcl | Trazodone Hcl | 140 | 26 |
| Metoprolol Tartrate | Metoprolol Tartrate | 137 | 23 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 130 | 35 |
| Clopidogrel | Clopidogrel Bisulfate | 125 | 26 |
| Pregabalin | Pregabalin | 117 | 16 |
| Montelukast Sodium | Montelukast Sodium | 111 | 20 |
| Spironolactone | Spironolactone | 106 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 105 | 26 |
| Alendronate Sodium | Alendronate Sodium | 98 | 21 |
| Meloxicam | Meloxicam | 97 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 90 | 18 |
| Jardiance | Empagliflozin | 86 | 23 |
| Bupropion Xl | Bupropion Hcl | 85 | 12 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 81 | 20 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 77 | 17 |
| Allopurinol | Allopurinol | 76 | 17 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 76 | 15 |
| Prednisone | Prednisone | 70 | 45 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 63 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 62 | 20 |
| Torsemide | Torsemide | 60 | 13 |
| Levetiracetam | Levetiracetam | 59 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 58 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 58 | 21 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 57 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 57 | 13 |
| Spiriva Respimat | Tiotropium Bromide | 56 | 12 |
| Chlorthalidone | Chlorthalidone | 54 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 54 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 54 | 11 |
| Myrbetriq | Mirabegron | 54 | suppressed |
| Simvastatin | Simvastatin | 54 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 52 | 11 |
| Mirtazapine | Mirtazapine | 52 | suppressed |
| Baclofen | Baclofen | 51 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 51 | suppressed |
| Famotidine | Famotidine | 50 | 12 |
| Clonidine Hcl | Clonidine Hcl | 49 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 49 | 13 |
| Metformin Hcl Er | Metformin Hcl | 48 | 13 |
| Novolog Flexpen | Insulin Aspart | 46 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 46 | suppressed |
| Januvia | Sitagliptin Phosphate | 44 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 44 | suppressed |
| Glipizide Er | Glipizide | 43 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 43 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 43 | suppressed |
| Ozempic | Semaglutide | 43 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 41 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 41 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 41 | 11 |
| Clobetasol Propionate | Clobetasol Propionate | 36 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 36 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 36 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 35 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 35 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 35 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 34 | 16 |
| Tramadol Hcl | Tramadol Hcl | 33 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 32 | suppressed |
| Linzess | Linaclotide | 32 | 11 |
| Glipizide | Glipizide | 31 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 29 | suppressed |
| Ibuprofen | Ibuprofen | 28 | suppressed |
| Glimepiride | Glimepiride | 27 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 27 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 27 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 26 | 21 |
| Bupropion Hcl Sr | Bupropion Hcl | 26 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 26 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 26 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 26 | suppressed |
| Acyclovir | Acyclovir | 25 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 24 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 23 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 23 | suppressed |
| Clonazepam | Clonazepam | 23 | suppressed |
| Entresto | Sacubitril/Valsartan | 23 | suppressed |
| Finasteride | Finasteride | 23 | suppressed |
| Ranolazine Er | Ranolazine | 23 | suppressed |
| Alprazolam | Alprazolam | 22 | suppressed |
| Clotrimazole | Clotrimazole | 22 | suppressed |
| Naproxen | Naproxen | 22 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 21 | 19 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 20 | suppressed |
| Fluconazole | Fluconazole | 19 | 13 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 18 | suppressed |
| Xarelto | Rivaroxaban | 18 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 17 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Gemtesa | Vibegron | 16 | suppressed |
| Memantine Hcl | Memantine Hcl | 16 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 15 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 15 | suppressed |
| Movantik | Naloxegol Oxalate | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Atenolol | Atenolol | 14 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Mounjaro | Tirzepatide | 14 | suppressed |
| Tretinoin | Tretinoin | 14 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 13 | suppressed |
| Ezetimibe | Ezetimibe | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 12 | suppressed |
| Amantadine | Amantadine Hcl | 11 | suppressed |
| Eszopiclone | Eszopiclone | 11 | suppressed |
| Ibu | Ibuprofen | 11 | suppressed |
| Klor-Con M20 | Potassium Chloride | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $21.12 · 1 records | GlaxoSmithKline, LLC. | BEXSERO, PEDIARIX, ROTARIX | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error